Chargement des cours...
Prévisions
| Acheter |
1 |
| Conserver |
1 |
| Vendre |
0 |
Actualités Accéder au fil d'actualités
Scilex Holding grants Vivasor revolving credit facility of $20 million
Scilex Holding has agreed a revolving credit facility of up to $20 million to Vivasor, which Vivasor can draw in tranches for up to 120 months after the facility becomes effective. Disbursements are at Scilex’s sole discretion and may be funded in cash, tradable Scilex securities or Datavault shares; the interest rate is 5% p.a. The SEC filing also states that Dr. Henry Ji is CEO of both companies and that Scilex simultaneously signed a term sheet for a planned $100 million investment with iHolding, while the company has high indebtedness and a low liquidity ratio. » Plus sur de.investing.com
Scilex signs term sheet for $100 million investment from iHolding of Kazakhstan
Scilex has signed a binding term sheet with iHolding Group LLP for a proposed $100 million capital increase. iHolding is to acquire newly issued shares at $15.00 per share, representing a 92% premium to the current price and would almost double the market capitalization. The proceeds are intended for expansion in healthcare and medtech, product development, acquisitions, working capital and IP expansion. The transaction remains subject to conditions such as due diligence, contractual closings, board approvals, shareholder consent and regulatory approvals. » Plus sur de.investing.com
Datavault AI receives $120 million financing from Scilex to expand edge network
Datavault AI has signed a binding term sheet for $120 million in capital from Scilex. In return, Scilex receives revenue participation rights (30% of gross revenues up to $250 million, then 15% up to $1.2 billion, and thereafter 5%). The funds are intended to build a quantum-capable edge network infrastructure in about 100 U.S. cities; Datavault has secured Nvidia GPUs with a market value of $1.2 billion and is using Available Infrastructure’s micro-edge data centers with zero-trust and quantum-resistant encryption. Initial deployments in New York and Philadelphia are planned for Q2 2026, with expansion envisaged to 25 sites within 12 months and 100 within 36 months after closing; the deal is to be completed in tranches through the end of 2026. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | juin 2026 | |
|---|---|---|
| Chiffre d'affaires | 6,70 Mio | 20,25% |
| Bénéfice brut | 986,61k | 82,44% |
| Bénéfice net | −99,45 Mio | 36,20% |
| EBITDA | −23,29 Mio | 31,94% |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 40,60 Mio€ |
Nombre d'actions | 8,49 Mio |
Plus haut/bas sur 52 semaines | 18,32€ - 2,24€ |
| Dividendes | Non |
Bêta | 1,74 |
Ratio P/E | −0,09 |
Ratio PEG | 0,00 |
Ratio P/B | −0,12 |
Ratio P/S | 1,50 |
Profil de l'entreprise
Die Scilex Holding Company, ein biopharmazeutisches Unternehmen, konzentriert sich auf die Entwicklung und Vermarktung von Nicht-Opioid-Produkten für die Behandlung von akuten und chronischen Schmerzen. Sein kommerzielles Produkt ist ZTlido 1,8%, ein verschreibungspflichtiges topisches Lidocain-Produkt zur Linderung von neuropathischen Schmerzen im Zusammenhang mit postherpetischer Neuralgie, einer Form von Nervenschmerzen nach einer Gürtelrose. Das Unternehmen bietet auch SP-102 an, eine viskose Gelformulierung von Kortikosteroid für epidurale Injektionen, die sich in einer klinischen Phase-III-Studie zur Behandlung von lumbosakralen radikulären Schmerzen befindet; SP-103, das sich in der klinischen Phase-II-Studie zur Behandlung von Kreuzschmerzen befindet; und SP-104, eine neuartige niedrig dosierte Naltrexonhydrochlorid-Formulierung mit verzögerter Freisetzung, die die klinische Phase-I-Studie zur Behandlung von Fibromyalgie abgeschlossen hat. Der Hauptsitz des Unternehmens befindet sich in Palo Alto, Kalifornien. Die Scilex Holding Company ist eine Tochtergesellschaft von Sorrento Therapeutics, Inc.
| Nom | Scilex Holding |
| PDG | Henry H. Ji |
| Siège social | Palo Alto,
ca États-Unis |
| Site web | |
| Secteur | Santé |
| Industrie | Biotechnologie |
| Introduction en bourse | 05/03/2021 |
| Employés | 34 |
Découvrir des actifs
Les actionnaires de Scilex Holding investissent également dans les actifs suivants

